Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.56 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25619503 | 1.00 | DNMT1 (0.56) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL25619498 | 0.90 | ADORA2A (0.53) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL25619489 | 0.90 | ADORA2A (0.53) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL23474154 | 0.87 | NT5E (0.67) | DNMT1DNMT3BADORA2AADORA2BADORA3 | |
| SCHEMBL23474181 | 0.87 | NT5E (0.67) | DNMT1DNMT3BADORA2AADORA2BADORA3 | |
| SCHEMBL28073065 | 0.85 | RNASEL (0.51) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL20009824 | 0.84 | DNMT1 (0.51) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL13769821 | 0.84 | ADORA3 (0.76) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL6829244 | 0.83 | DNMT1 (0.48) | DNMT1DNMT3BRNASELADORA2AADORA2B | |
| SCHEMBL6826877 | 0.83 | DNMT1 (0.49) | DNMT1DNMT3BRNASELADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | DNMT1 1173/4885DNMT3B 1423/4885RNASEL 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.